Control vaccine

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

9 competitors in Respiratory Syncytial Virus

#DrugCompanyPhaseTrials

1

Mrna-1345

Moderna

Phase 3

42

RSV Vaccine 1

Sanofi

Phase 2

43

ABO1105

SSuzhou Abogen Biosciences Co., Ltd.

Phase 2

24

Mrna-1365

Moderna

Phase 1

15

Bivalent RSV Vaccine (IN006)

SShenzhen Shenxin Biotechnology Co., Ltd

Phase 1

26

Control vaccine

GSK

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years

Recruiting·GSK·Preclinical·NCT07628049·1,456 enrolled

Respiratory Syncytial Virus Immunization1 trial

A Phase 1/2, Randomized, Controlled, Observer-Blind Study in Adults 60 Years of Age and Older to Evaluate the Immunogenicity and Safety of Different Dose Levels of a Bivalent Vaccine Candidate Against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)

Recruiting·Sanofi·Preclinical·NCT07734649·2,400 enrolled

Details

Drug Info

Related News